Abstract
COVID-19 infection affects many systems in the body including the coagulation mechanisms. Imbalance between pro-coagulant and anticoagulant activities causes a roughly nine times higher risk for pulmonary embolism (PE) in COVID-19 patients. The reported incidence of PE in COVID-19 patients ranges from 3 to 26%. There is an increased risk of PE in hospitalized patients with lower mobility and patients requiring intensive care therapy. Obesity, atrial fibrillation, raised pro-inflammatory markers, and convalescent plasma therapy increases the risk of PE in COVID-19 patients. Endothelial injury in COVID-19 patients causes loss of vasodilatory, anti-adhesion and fibrinolytic properties. Viral penetration and load leads to the release of cytokines and von Willebrand factor, which induces thrombosis in small and medium vessels. D-dimers elevation gives strong suspicion of PE in COVID-19 patients, and normal D-dimer levels effectively rule it out. Point of care echocardiogram may show right heart dilatation, thrombus in heart or pulmonary arteries. DVT increases the risk of developing PE. The gold standard test for the diagnosis of PE is CTPA (computerized tomographic pulmonary angiography) which also gives alternative diagnosis in the absence of PE. Therapeutic anticoagulation is the corner stone in the management of PE and commonly used anticoagulants are LMWH (low molecular weight heparin) and UFH (unfractionated heparin). Mortality in COVID-19 patients with PE is up to 43% compared to COVID patients without PE being around 3%.
Highlights
COVID-19 infection is primarily a respiratory viral infection, initially described in China and despite restrictive and preventive measures, it spread quickly and within few months became a global pandemic
Hypercoagulable state is a well-known complication in severely ill COVID-19 patients. This increases the risk of thromboembolism, pulmonary embolism (PE) [1]
All hospitalized COVID-19 patients and patients admitted to intensive care unit (ICU) should be on thromboprohylaxis, and these patients with increase in inflammatory markers (CRP and Platelets) and D-dimer levels more than 3 ug/ml should be therapeutic dosage of LMWH or unfractionated heparin (UFH) depending on their organ dysfunction renal functions [9]
Summary
COVID-19 infection is primarily a respiratory viral infection, initially described in China and despite restrictive and preventive measures, it spread quickly and within few months became a global pandemic. Pulmonary Embolism infection, it can cause multiple organ dysfunctions and is a constant threat to the life. Hypercoagulable state is a well-known complication in severely ill COVID-19 patients. This increases the risk of thromboembolism, pulmonary embolism (PE) [1]. The presence of pulmonary embolism in COVID-19 patients creates a challenging clinical scenario due to their already compromised respiratory function. Recognition and therapeutic intervention are critical for better patient management and a positive outcome. We will discuss the occurrence of PE in COVID-19 infection in following sub-headings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
